LIVINGLIVING
DIABELOOP
KIT THAT'S COMING SOON
Diabeloop was founded
in 2015 and is based
in Grenoble, France.
Most members
of staff are based
here, though there is also an office in
Paris. In November 2018, Diabeloop's
first medical device, DBLG1, was CE
marked. This company is working on
delivering the system in Europe (France
and Germany at first) and later in the US.
Founder and CEO Eric Hunekerhas
experience medical devices field at GE
Healthcare, where he managed the
international localization business to a
ten-fold growth in sales. He has been
the driver of the technology side of
development.of Diabeloop's solutions
when Guillaume Charpentier co-founder
was looking into transforming his medical
project into a commerically available
solution. Co-CEO Mark Julien looks after
the financing and fund-raising.
Stephanie Jegu works for the
company looking after its brand and
communications. This is the first time
she's worked in the medical field, having
previously worked with companies
outside of the healthcare sector. Jegu has
had Type I diabetes for nearly a decade,
so can easily add insights as to the benefit
of the system. She explains, "DBLG1 is
described as a 'hybrid closed-loop insulin
delivery system'. It's 'hybrid' because
although the insulin delivery is automated
and personalized, the user still has to
enter information, such as carbs intake
and physical activity for the system to be
able to anticipate glucose variation and
adapt delivery and/or recommendations.
The system is designed to be easy to use
and has a friendly interface."
At the end of 2020, another device of
Diabeloop, DBL-hu, obtained CE-mark.
It targets highly unstable diabetes, which
is very complex to manage and people
who have it struggle to gain and maintain
decent blood glucose balance. The
clinical and metabolic consequences are
debilitating and lead to severe progressive
complications can develop. Diabeloop's
DBL-hu modular technological solution
is designed to provide people with
complex diabetes a more stable daily life,
reduced psychological distress, reduced
hypoglycemia and better overall diabetes
control.
Robust trials
Diabeloop pursues a programme of
clinical studies. Results for the DBL4K
clinical study with 15 participating children
are set to be published soon, and a study
on adolescents, (including unannounced
meal functionality) should start in 2021
Any closed loop system involves
a continuous glucose monitor (CGM)
working with an insulin delivery device via
an algorithm). Diabeloop currently works
with ViCentra's Kaleido insulin pump in
We talk to the people bringing us a closed loop system from
their base in Grenoble, France.
continued over
Diabeloop's Stephanie Jegu
"The system is designed
to be easy to use and
has a friendly interface.
- Stephanie Jegu,
Diabeloop